Immunic (IMUX) Common Equity (2013 - 2026)

Immunic (IMUX) has 14 years of Common Equity data on file, last reported at $151.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 2960.47% year-over-year to $151.2 million; the trailing twelve-month figure through Mar 2026 stood at $151.2 million (up 2960.47% YoY), and the FY2025 full-year result was -$6.7 million, down 136.21% from the prior year.
• Common Equity advanced to $151.2 million in Q1 2026, from -$6.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $151.2 million in Q1 2026 to a low of -$6.7 million in Q4 2025.
• A 5-year average of $65.7 million and a median of $63.6 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 136.21% in 2025 and soared 2960.47% in 2026, its largest moves.
• Tracing IMUX's Common Equity over 5 years: stood at $113.7 million in 2022, then plunged by 74.55% to $28.9 million in 2023, then plunged by 36.3% to $18.4 million in 2024, then sank by 136.21% to -$6.7 million in 2025, then soared by 2366.34% to $151.2 million in 2026.
• Business Quant data shows IMUX's Common Equity at $151.2 million in Q1 2026, -$6.7 million in Q4 2025, and $10.5 million in Q3 2025.